Funding Opportunity PAR-19-161 from the NIH Guide for Grants and Contracts. The purpose of this NIDCR Mentored Career Development Award is to enhance the diversity of the independently funded dental, oral and craniofacial research workforce by providing a mentored research experience for eligible postdoctoral fellows and early career faculty from diverse backgrounds, including those who are from groups underrepresented in the biomedical and behavioral sciences. This award provides salary and research support for a sustained period of protected time for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit to the companion Clinical Trial Required FOA (PAR-18-359). Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator must apply to companion FOA (PAR-19-NNN).

Funding Opportunity PAR-19-152 from the NIH Guide for Grants and Contracts. The purpose of the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program is to provide highly qualified dentists in NIH Intramural postdoctoral fellowship positions with an opportunity to receive further mentored research experience in the NIH Intramural program, and then to provide them with independent funding to facilitate the transition of their research programs as new investigators at extramural institutions. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial or basic experimental study with humans led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to one of the companion FOAs. Applicants proposing studies conducted with specific applications toward processes or products in mind should submit to the companion Clinical Trial Required (PAR-18-360). Applicants proposing basic experimental studies in humans referred to in NOT-OD-18-212 as prospective basic science studies involving human participants" should apply to the companion Basic Experimental Studies with Humans FOA (PAR-19-NNN).

Funding Opportunity PAR-19-151 from the NIH Guide for Grants and Contracts. The purpose of the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program is to provide highly qualified dentists in NIH Intramural postdoctoral fellowship positions with an opportunity to receive further mentored research experience in the NIH Intramural program, and then to provide them with independent funding to facilitate the transition of their research programs as new investigators at extramural institutions. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should apply to the companion Clinical Trial Required FOA (PAR-18-360). Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to companion FOA (PAR-19- NNN).

Notice NOT-AR-19-034 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-19-153 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 1224 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers.

Funding Opportunity PAR-19-156 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies, and engage biomedical researchers or clinicians throughout the project. The goal of the program is to support projects that can realize meaningful solutions within 5 10 years.

Funding Opportunity PAR-19-157 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies, and engage biomedical researchers or clinicians throughout the project. The goal of the program is to support projects that can realize meaningful solutions within 5 10 years.

Funding Opportunity PAR-19-149 from the NIH Guide for Grants and Contracts. The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.

Funding Opportunity PAR-19-150 from the NIH Guide for Grants and Contracts. The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of Exploratory/Developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.

Funding Opportunity PAR-19-158 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.

Funding Opportunity PAR-19-159 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.

Funding Opportunity PAR-19-146 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability in the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA NIH wishes to stimulate research in 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics, 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest, 3) Later stage lead optimization to improve efficacy and pharmacokinetics, and 4) Initial drug metabolism and pharmacokinetic (DMPK). Emphasis will be placed on projects that provide novel approaches to identify potential therapeutic agents.

Funding Opportunity PAR-19-147 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA NIMH and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents.

Funding Opportunity PAR-19-145 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity announcement is to support meritorious research projects that involve secondary data analyses of existing oral or craniofacial database resources, or to develop needed statistical methodology for analyzing oral and craniofacial data using existing oral or craniofacial databases. The R03 grant mechanism supports research limited in time and amount for studies in categorical program areas.

Funding Opportunity PAR-19-155 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is to support studies that are scientifically essential, yet also sufficient, for investigators to make definitive decisions that inform the final designs of important Phase II and beyondclinical trials within NHLBI's mission; that is, clinical trials with the primary intent of testing the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and treatment of heart, lung, blood, and sleep disorders. This mechanism may be used to test the feasibility of novel and efficient (pragmatic) trial designs, as well as determine the feasibility of an intervention, intervention parameters, subject availability, or other information essential to complete the design of a trial. Applications should demonstrate that the proposed studies are both necessary and sufficient to permit definitive decisions about the final design of the subsequent clinical trial. Applicants who propose solely to write a protocol or manual of operations,to develop infrastructure for a clinical trial, or implement a fully designed trialwill not be considered appropriate for this announcement. Please note that NHLBI supports other funding opportunities for clinical trials-see https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clinical-trials-optimization for information on other NHLBI clinical trial funding opportunity announcements. In contrast to the planning or study start up phase of other NHLBI clinical trial FOAs, the R34 mechanism is intended to provide new i?n?f?o?r?m?a?t?i?o?n that answers a scientific question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial.

Notice NOT-DA-19-015 from the NIH Guide for Grants and Contracts

Notice NOT-OD-19-053 from the NIH Guide for Grants and Contracts

Notice NOT-GM-19-012 from the NIH Guide for Grants and Contracts

Notice NOT-OD-19-052 from the NIH Guide for Grants and Contracts

Notice NOT-GM-19-013 from the NIH Guide for Grants and Contracts